Global Surge In Cancer Cases And Its Effect On The Market Is Supporting Development Across The Immuno-Oncology Drugs Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Growth In Market Value Is Anticipated For The Immuno-Oncology Drugs Market Between 2026 And 2030?

The immuno-oncology drugs market size has experienced substantial expansion in recent years. It is projected to increase from $120.37 billion in 2025 to $136.15 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.1%. The historical growth in this market can be linked to factors such as the limited availability of immuno-oncology drugs, a reliance on conventional chemotherapy, the rising prevalence of cancers like melanoma and lung cancer, growing oncology-focused research initiatives, and early regulatory approvals for monoclonal antibodies.

The immuno-oncology drugs market is projected to experience swift expansion in the coming years. Its size is anticipated to reach **$226.31 billion in 2030**, demonstrating a compound annual growth rate (CAGR) of **13.5%**. This growth over the forecast period is attributable to factors such as the development of bispecific antibodies and oncolytic virus therapies, the broadening of personalized immunotherapy solutions, increased investment in adoptive cell transfer therapies, rising healthcare spending on cancer treatment, and the incorporation of digital platforms for patient monitoring and clinical trials. Key trends during this period encompass the increasing adoption of immune checkpoint inhibitors across various cancer types, an upsurge in the development of cancer vaccines and adoptive cell therapies, a heightened emphasis on personalized immuno-oncology treatments, the expansion of hospital and ambulatory surgical center-based immunotherapy programs, and a rise in clinical trials and research initiatives concerning monoclonal antibodies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3455&type=smp

What Important Drivers Are Powering The Immuno-Oncology Drugs Market Growth?

The projected increase in cancer diagnoses is set to boost the expansion of the immuno-oncology drugs market. Cancer is characterized by the uncontrolled multiplication of abnormal cells, potentially migrating to other bodily regions and impairing typical physiological processes. The escalation in cancer cases is attributable to an aging populace, evolving lifestyle habits, and improvements in diagnostic methods. Immuno-oncology drugs contribute to this by stimulating the body’s immune system to identify and eliminate cancer cells, thereby providing more effective and precise treatment options. For instance, in 2023, Cancer Australia, an Australia-based government agency, estimated 164,694 new cancer cases were diagnosed and 51,269 deaths occurred, with prostate, breast, melanoma, colorectal, and lung cancers being the most common, while rare cancers represented about one-third of diagnoses and 42% of deaths. Thus, the rising occurrence of cancer cases is driving the growth of the immuno-oncology drugs market.

How Is The Immuno-Oncology Drugs Market Structured Across Different Market Segments?

The immuno-oncology drugs market covered in this report is segmented –

1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Other Types

2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application

3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

2) By Immune System Modulators: Cytokines, Interferons, Colony-Stimulating Factors

3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies, Bispecific Antibodies

4) By Cancer Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

5) By Other Types: Adoptive Cell Transfer Therapies, Oncolytic Virus Therapies

What Trends Are Influencing The Immuno-Oncology Drugs Market?

Leading companies operating in the immuno-oncology drugs market are forming alliances to develop and bring to market a novel checkpoint antibody, aiming to enhance the effectiveness of cancer treatments. These strategic collaborations stimulate innovation through interdisciplinary knowledge sharing, which leads to the quicker creation of combination therapies, personalized treatments, and advanced drug delivery systems. For example, in March 2023, BioNTech SE, a Germany-based company, joined forces with OncoC4 Inc, a US-based pharmaceutical company, to jointly develop and commercialize a checkpoint antibody, specifically the anti-CTLA-4 monoclonal antibody candidate known as ONC-392. This alliance seeks to improve cancer treatment options for a range of solid tumor indications.

Which Firms Are Competing In The Immuno-Oncology Drugs Market?

Major companies operating in the immuno-oncology drugs market are F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals.

Access The Complete Immuno-Oncology Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report

Which Regional Market Leads The Immuno-Oncology Drugs Market?

North America was the largest region in the immuno-oncology drugs market in 2025. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Immuno-Oncology Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=3455&type=smp

Browse Through More Reports Similar to the Global Immuno-Oncology Drugs Market 2026, By The Business Research Company

Veterinary Laboratory Testing Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-laboratory-testing-services-global-market-report

Dermatitis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Veterinary Diagnostic Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-diagnostic-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795